无菌性全髋翻修指征的并发症风险异质性及时序趋势
基于保险理赔数据库的倾向匹配研究纳入3,876例首次无菌性全髋翻修患者,比较假体周围骨折、脱位和机械失效三种指征的术后结局。假体周围骨折翻修感染风险较高且资源消耗大,而脱位翻修的再翻修和再手术风险最高;2016至2022年假体周围骨折翻修量增加282%,但各指征感染无进展。
要点
- 假体周围骨折翻修5年PJI发生率11%,高于脱位10%和机械失效7%。
- 脱位翻修5年再翻修率13%、再手术率15%,均为三组最高。
- 2016至2022年假体周围骨折翻修量增加282%,感染无改善。
核心结论
- 假体周围骨折翻修是感染倾向且资源密集的翻修场景,但脱位翻修的再翻修和再手术风险最高。
- 不稳定仍是具有挑战性的翻修指征,强调需按指征进行风险分层。
研究设计与样本
- 使用保险理赔数据库识别首次全髋翻修患者,按侧别诊断编码分层为无菌性指征。
- 三组按人口学和合并症进行倾向匹配,共纳入3,876例匹配患者。
- 结局评估至术后5年,采用卡方检验、Kaplan-Meier分析、Cox回归和方差分析,并评估2016至2022年年度趋势。
主要发现
- PJI发生率从90天(假体周围骨折7%、脱位6%、机械失效4%;P=0.005)至5年(11%、10%、7%;P=0.015)存在组间差异。
- 5年再翻修率(假体周围骨折8%、脱位13%、机械失效10%;P<0.001)和再手术率(10%、15%、11%;P=0.002)以脱位最高。
- Cox回归显示假体周围骨折PJI风险增加(HR=1.43),脱位PJI风险增加(HR=1.35)。
- 脱位再翻修风险增加(HR=1.28),再手术风险增加(HR=1.26)。
- 假体周围骨折翻修90天输血率、再入院率更高且住院时间更长(P<0.05)。
关键数值与推荐
- 2016至2022年,假体周围骨折翻修量增加282%,脱位翻修量增加8.7%。
- 假体周围骨折无再翻修生存率从2016年89.5%改善至2022年94.2%,脱位从83.2%改善至86.9%。
- 2016至2022年各指征无PJI生存率均无改善。
临床怎么用
- 对假体周围骨折翻修患者应关注感染预防和围手术期资源准备。
- 对脱位翻修患者应重视再翻修和再手术风险,加强稳定性评估与随访。
- 按翻修指征进行风险分层,有助于个体化咨询和并发症防控。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With the increasing burden of revision total hip arthroplasty (rTHA), the comparative postoperative risk profiles among aseptic rTHA indications remain incompletely understood. This study evaluated postoperative periprosthetic joint infection (PJI), reoperation, and rerevision following rTHA for periprosthetic fracture (PPFx), dislocation, and mechanical failure. Secondarily, medical complications and temporal trends were assessed. METHODS: Using an insurance claims database, first-time rTHA patients were identified using side-specific diagnosis coding and stratified by aseptic indication for rTHA. Groups were propensity-matched on demographics and comorbidities. Outcomes were assessed up to five years using Chi-square tests, Kaplan-Meier analyses, Cox regressions, and analyses of variance. Temporal trends were evaluated annually from 2016 to 2022. RESULTS: Among 3,876 matched patients, PJI incidence differed across groups from 90 days (periprosthetic fracture: 7%; dislocation: 6%; mechanical failure: 4%; P = 0.005) through five years (11, 10, 7%; P = 0.015). The five-year rerevision (PPFx: 8%, dislocation: 13%, mechanical failure: 10%; P < 0.001) and reoperation (10, 15, 11%; P = 0.002) rates were highest for dislocation. Cox regressions identified increased PJI risk for PPFx (hazard ratio (HR): 1.43) and dislocation (HR: 1.35). Dislocation demonstrated increased re-revision (HR: 1.28) and reoperation (HR: 1.26) risks. Revisions for PPFx demonstrated higher 90-day transfusion and readmission rates and longer hospital stays (P < 0.05). From 2016 to 2022, rTHA for PPFx increased by 282% and dislocation by 8.7%. Rerevision-free survival improved for PPFx (from 89.5% in 2016 to 94.2% in 2022) and dislocation (83.2 to 86.9%). The PJI-free survival showed no improvement across indications from 2016 to 2022. CONCLUSIONS: Although rTHA for PPFx may represent an infection-prone and resource-intensive revision scenario, revision for dislocation carried the highest risk of rerevision and reoperation. Although rising rTHAs for PPFx warrant attention, instability remains a challenging revision indication, underscoring the importance of indication-specific risk stratification.
引用
- Bera SR, Brady TT, Adamczyk AP, et al. Heterogeneity in Complication Risks and Temporal Trends Across Aseptic Indications for Revision Total Hip Arthroplasty. J Arthroplasty. 2026. PMID: 42448246. doi:10.1016/j.arth.2026.06.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。